Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis

[1]  M. Shimizu,et al.  Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice , 2020, International journal of molecular sciences.

[2]  S. O'keefe,et al.  Fiber, Fat, and Colorectal Cancer: New Insight into Modifiable Dietary Risk Factors , 2019, Current Gastroenterology Reports.

[3]  M. Velusamy,et al.  Suppression of Human Platelet Activation via Integrin αIIbβ3 Outside-In Independent Signal and Reduction of the Mortality in Pulmonary Thrombosis by Auraptene , 2019, International journal of molecular sciences.

[4]  N. Horita,et al.  Chemoprevention of colorectal cancer: Past, present, and future , 2019, Cancer science.

[5]  Huawei Zeng,et al.  Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer , 2019, International journal of molecular sciences.

[6]  M. Slack,et al.  A Systematic Review of Population-Based Studies on Pain Self-Management Strategies and Outcomes , 2018 .

[7]  Wei Jia,et al.  Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.

[8]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[9]  S. Ng,et al.  The Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21 st Century: A Systematic Review of Population-Based Studies , 2017 .

[10]  S. Marchianò,et al.  Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases , 2017, Front. Pharmacol..

[11]  C. Levy,et al.  FXR Agonists: From Bench to Bedside, a Guide for Clinicians , 2016, Digestive Diseases and Sciences.

[12]  Takuji Tanaka,et al.  Cimetidine and Clobenpropit Attenuate Inflammation-Associated Colorectal Carcinogenesis in Male ICR Mice , 2016, Cancers.

[13]  A. Carino,et al.  Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists , 2016, Scientific Reports.

[14]  M. Vicario,et al.  The intestinal barrier function and its involvement in digestive disease. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[15]  Takuji Tanaka,et al.  Utility of Apc-mutant rats with a colitis-associated colon carcinogenesis model for chemoprevention studies , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  Takuji Tanaka,et al.  Inhibitory effects of astaxanthin on azoxymethane-induced colonic preneoplastic lesions in C57/BL/KsJ-db/db mice , 2014, BMC Gastroenterology.

[17]  Takuji Tanaka,et al.  A newly synthesized compound, 4′‐geranyloxyferulic acid–N(omega)‐nitro‐l‐arginine methyl ester suppresses inflammation‐associated colorectal carcinogenesis in male mice , 2014, International journal of cancer.

[18]  S. Genovese,et al.  Nelumal A, the Active Principle of Ligularia nelumbifolia, is a Novel Aromatase Inhibitor , 2014, Natural product communications.

[19]  Takuji Tanaka,et al.  Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats , 2014, Oncology letters.

[20]  Takuji Tanaka,et al.  A novel aromatic mutagen, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one (ABAQ), induces colonic preneoplastic lesions in mice , 2014, Toxicology reports.

[21]  A. Gewirtz,et al.  Faculty Opinions recommendation of Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. , 2013 .

[22]  T. Ohno,et al.  Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. , 2012, Cancer letters.

[23]  S. Genovese,et al.  Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist. , 2012, Bioorganic & medicinal chemistry letters.

[24]  Yunwei Wang,et al.  Dietary fat-induced taurocholic acid production promotes pathobiont and colitis in IL-10−/− mice , 2012, Nature.

[25]  W. Blaner,et al.  Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. , 2012, Carcinogenesis.

[26]  Takuji Tanaka,et al.  Preventive Effects of Curcumin on the Development of Azoxymethane-Induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Obese Mice , 2012, Nutrition and cancer.

[27]  D. Thompson,et al.  A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys. , 2011, Journal of pharmaceutical sciences.

[28]  Peter D Siersema,et al.  Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. , 2011, Biochimica et biophysica acta.

[29]  R. Kiss,et al.  Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines. , 2011, Bioorganic & medicinal chemistry letters.

[30]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[31]  S. Genovese,et al.  Auraptene: a natural biologically active compound with multiple targets. , 2011, Current drug targets.

[32]  P. Siersema,et al.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.

[33]  Takuji Tanaka,et al.  Pitavastatin inhibits azoxymethane‐induced colonic preneoplastic lesions in C57BL/KsJ‐db/db obese mice , 2010, Cancer science.

[34]  E. Distrutti,et al.  The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1 , 2009, The Journal of Immunology.

[35]  Takuji Tanaka,et al.  Supplementation with Branched-chain Amino Acids Inhibits Azoxymethane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice , 2009, Clinical Cancer Research.

[36]  Ann M. Thomas,et al.  Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development , 2009, Journal of Pharmacology and Experimental Therapeutics.

[37]  Takuji Tanaka,et al.  Citrus Compounds Inhibit Inflammation- and Obesity-Related Colon Carcinogenesis in Mice , 2008, Nutrition and cancer.

[38]  D. Moore,et al.  FXR: a metabolic regulator and cell protector , 2008, Cell Research.

[39]  Takuji Tanaka,et al.  EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. , 2008, Molecular medicine reports.

[40]  Takuji Tanaka,et al.  Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis‐related colon carcinogenesis in mice , 2006, International journal of cancer.

[41]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[42]  Dae-Joong Kang,et al.  Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.

[43]  Takuji Tanaka,et al.  Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands , 2005, BMC Cancer.

[44]  S. Itzkowitz,et al.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[45]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[46]  Takuji Tanaka,et al.  A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate , 2003, Cancer science.

[47]  Takuji Tanaka,et al.  Citrus auraptene exerts dose-dependent chemopreventive activity in rat large bowel tumorigenesis: the inhibition correlates with suppression of cell proliferation and lipid peroxidation and with induction of phase II drug-metabolizing enzymes. , 1998, Cancer research.

[48]  Takuji Tanaka,et al.  Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by citrus auraptene in rats. , 1998, Carcinogenesis.

[49]  A. Murakami,et al.  Auraptene, a Citrus Coumarin, Inhibits 12‐0‐Tetradecanoylphorbol‐13‐acetate‐induced Tumor Promotion in ICR Mouse Skin, Possibly through Suppression of Superoxide Generation in Leukocytes , 1997, Japanese journal of cancer research : Gann.

[50]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[51]  C. Teng,et al.  Antiplatelet actions of some coumarin compounds isolated from plant sources. , 1992, Thrombosis research.

[52]  D. Tousoulis,et al.  The Role of Inflammation , 2018 .

[53]  M. Mikov,et al.  The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[54]  A. Schetter,et al.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. , 2010, Carcinogenesis.

[55]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.